Asset Details
Do you wish to reserve the book?
Advanced glycation end products measured by skin autofluorescence and subclinical cardiovascular disease: the Rotterdam Study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Advanced glycation end products measured by skin autofluorescence and subclinical cardiovascular disease: the Rotterdam Study
Do you wish to request the book?
Advanced glycation end products measured by skin autofluorescence and subclinical cardiovascular disease: the Rotterdam Study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Advanced glycation end products measured by skin autofluorescence and subclinical cardiovascular disease: the Rotterdam Study
2023
Overview
Background
Advanced glycation end products (AGEs) have been linked to cardiovascular disease (CVD), especially coronary heart disease (CHD), but their role in CVD pathogenesis remains unclear. Therefore, we investigated cross-sectional associations of skin AGEs with subclinical atherosclerosis, arterial stiffness, and hypertension after confirming their relation with CHD.
Methods
In the population-based Rotterdam Study, skin AGEs were measured as skin autofluorescence (SAF). Prevalent MI was obtained from digital medical records. Carotid plaques, carotid intima-media thickness (IMT), coronary artery calcification (CAC), pulse wave velocity (PWV), and hypertension were assessed. Associations of SAF with endophenotypes were investigated in logistic and linear regression models adjusting for common cardiovascular risk factors. Effect modification by sex, diabetes mellitus, and chronic kidney disease (CKD) was tested.
Results
3001 participants were included (mean age 73 (SD 9) years, 57% women). One unit higher SAF was associated with the presence of carotid plaques (OR 1.2 (0.92, 1.57)), a higher max IMT (0.08 SD (0.01, 0.15)), higher CAC (OR 2.2 (1.39, 3.48)), and PWV (0.09 SD (0.01, 0.16)), but not with hypertension (OR 0.99 (0.81, 1.21)). The associations with endophenotypes were more pronounced in men and participants with diabetes or CKD with significant interactions.
Conclusions
Previously documented associations between SAF and CVD, also found in our study, may be explained by the endophenotypes atherosclerosis and arterial stiffness, especially in men and individuals with diabetes or CKD, but not by hypertension. Longitudinal studies are needed to replicate these findings and to test if SAF is an independent risk factor or biomarker of CVD.
Trial registration
: The Rotterdam Study has been entered into the Netherlands National Trial Register (NTR;
www.trialregister.nl
) and the WHO International Clinical Trials Registry Platform (ICTRP;
www.who.int/ictrp/network/primary/en/
) under shared catalogue number NTR6831.
Publisher
BioMed Central,Springer Nature B.V,BMC
Subject
Advanced glycation end products
/ Advanced glycosylation end products
/ Aged
/ Atherosclerosis - complications
/ Cardiovascular Diseases - diagnostic imaging
/ Cardiovascular Diseases - epidemiology
/ Carotid Intima-Media Thickness
/ Coronary artery calcification
/ Diabetes
/ Female
/ Glycation End Products, Advanced
/ Humans
/ Hypertension - complications
/ Male
/ Medicine
/ Plaque
/ Plaque, Atherosclerotic - complications
/ Plaques
/ Renal Insufficiency, Chronic - complications
/ Renal Insufficiency, Chronic - diagnosis
/ Renal Insufficiency, Chronic - epidemiology
/ Skin
